FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249297159> ?p ?o ?g. }

• W4249297159 endingPage "S1" @default.
• W4249297159 startingPage "S1" @default.
• W4249297159 abstract "To test the impact of 1g of tranexamic acid after cesarean delivery on the incidence of postpartum hemorrhage (PPH). In a multicenter, double-blind, randomized controlled trial, we randomly assigned women with a cesarean before or during labor at ≥ 34 gestation weeks to receive a prophylactic uterotonic and 1 g of tranexamic acid (TXA) or placebo. The primary outcome was an objective calculated blood loss > 1000 ml or a red blood cell transfusion by Day 2 after delivery. Secondary outcomes were other measures of postpartum blood loss and potential adverse effects of TXA up to 3 months after delivery. Of the 4551 randomized women, 4431 had cesareans, 4153 of whom (93.7%) were assessed for primary outcome. The primary outcome occurred in 556 of 2086 women (26.7%) in the TXA and in 653 of 2067 (31.6%) in the placebo group (adjusted risk ratio, 0.84; 95% confidence interval [CI], 0.75 to 0.94; P<0.01). Mean rates for blood loss-related laboratory outcomes were lower in the TXA than the placebo group: mean calculated blood loss (680±748 versus 787±750 ml) and mean peripartum change in hemoglobin and hematocrit (all adjusted P-values <0.001). There were no significant between-group differences in the rates of these hemorrhage-related outcomes: mean gravimetrically estimated blood loss, provider-assessed clinically significant PPH, use of additional uterotonic agents, and postpartum transfusion (all adjusted P>0.05). Vomiting or nausea was more frequent in the TXA than the placebo group (42.7% versus 35.9%, adjusted P<0.001). At 3 months postpartum, thromboembolic events had occurred in 0.4% (8/2079) of the TXA and 0.1% (2/2086) of the placebo group (adjusted risk ratio, 3.99; 95% CI, 0.85 to 18.81; adjusted P=0.08). Among women with cesarean receiving prophylactic uterotonics, tranexamic acid treatment resulted in a significantly lower rate than placebo of calculated blood loss > 1000 ml or transfusion by day 2, but did not reduce hemorrhage-related secondary clinical outcomes (ClinicalTrials.gov numberNCT03431805)." @default.
• W4249297159 created "2022-05-12" @default.
• W4249297159 creator A5001650037 @default.
• W4249297159 creator A5010301916 @default.
• W4249297159 creator A5021787063 @default.
• W4249297159 creator A5021867458 @default.
• W4249297159 creator A5022386988 @default.
• W4249297159 creator A5028069517 @default.
• W4249297159 creator A5032606627 @default.
• W4249297159 creator A5035416209 @default.
• W4249297159 creator A5037052804 @default.
• W4249297159 creator A5037923520 @default.
• W4249297159 creator A5039668351 @default.
• W4249297159 creator A5049913129 @default.
• W4249297159 creator A5052004467 @default.
• W4249297159 creator A5055431095 @default.
• W4249297159 creator A5059256161 @default.
• W4249297159 creator A5062343791 @default.
• W4249297159 creator A5065143968 @default.
• W4249297159 creator A5078408177 @default.
• W4249297159 creator A5078722840 @default.
• W4249297159 creator A5082513352 @default.
• W4249297159 creator A5087353973 @default.
• W4249297159 creator A5090138136 @default.
• W4249297159 creator A5090223417 @default.
• W4249297159 creator A5090412856 @default.
• W4249297159 date "2021-02-01" @default.
• W4249297159 modified "2023-10-16" @default.
• W4249297159 title "1 Tranexamic acid for the prevention of postpartum hemorrhage after cesarean delivery: the TRAAP2 trial" @default.
• W4249297159 doi "https://doi.org/10.1016/j.ajog.2020.12.103" @default.
• W4249297159 hasPublicationYear "2021" @default.
• W4249297159 type Work @default.
• W4249297159 citedByCount "3" @default.
• W4249297159 countsByYear W42492971592022 @default.
• W4249297159 crossrefType "journal-article" @default.
• W4249297159 hasAuthorship W4249297159A5001650037 @default.
• W4249297159 hasAuthorship W4249297159A5010301916 @default.
• W4249297159 hasAuthorship W4249297159A5021787063 @default.
• W4249297159 hasAuthorship W4249297159A5021867458 @default.
• W4249297159 hasAuthorship W4249297159A5022386988 @default.
• W4249297159 hasAuthorship W4249297159A5028069517 @default.
• W4249297159 hasAuthorship W4249297159A5032606627 @default.
• W4249297159 hasAuthorship W4249297159A5035416209 @default.
• W4249297159 hasAuthorship W4249297159A5037052804 @default.
• W4249297159 hasAuthorship W4249297159A5037923520 @default.
• W4249297159 hasAuthorship W4249297159A5039668351 @default.
• W4249297159 hasAuthorship W4249297159A5049913129 @default.
• W4249297159 hasAuthorship W4249297159A5052004467 @default.
• W4249297159 hasAuthorship W4249297159A5055431095 @default.
• W4249297159 hasAuthorship W4249297159A5059256161 @default.
• W4249297159 hasAuthorship W4249297159A5062343791 @default.
• W4249297159 hasAuthorship W4249297159A5065143968 @default.
• W4249297159 hasAuthorship W4249297159A5078408177 @default.
• W4249297159 hasAuthorship W4249297159A5078722840 @default.
• W4249297159 hasAuthorship W4249297159A5082513352 @default.
• W4249297159 hasAuthorship W4249297159A5087353973 @default.
• W4249297159 hasAuthorship W4249297159A5090138136 @default.
• W4249297159 hasAuthorship W4249297159A5090223417 @default.
• W4249297159 hasAuthorship W4249297159A5090412856 @default.
• W4249297159 hasConcept C126322002 @default.
• W4249297159 hasConcept C131872663 @default.
• W4249297159 hasConcept C141071460 @default.
• W4249297159 hasConcept C142724271 @default.
• W4249297159 hasConcept C168563851 @default.
• W4249297159 hasConcept C203092338 @default.
• W4249297159 hasConcept C204787440 @default.
• W4249297159 hasConcept C27081682 @default.
• W4249297159 hasConcept C2776176026 @default.
• W4249297159 hasConcept C2779494336 @default.
• W4249297159 hasConcept C2779637338 @default.
• W4249297159 hasConcept C2780014101 @default.
• W4249297159 hasConcept C2780056395 @default.
• W4249297159 hasConcept C2780580376 @default.
• W4249297159 hasConcept C2780659260 @default.
• W4249297159 hasConcept C2780852908 @default.
• W4249297159 hasConcept C2780959883 @default.
• W4249297159 hasConcept C2991743468 @default.
• W4249297159 hasConcept C42219234 @default.
• W4249297159 hasConcept C71924100 @default.
• W4249297159 hasConceptScore W4249297159C126322002 @default.
• W4249297159 hasConceptScore W4249297159C131872663 @default.
• W4249297159 hasConceptScore W4249297159C141071460 @default.
• W4249297159 hasConceptScore W4249297159C142724271 @default.
• W4249297159 hasConceptScore W4249297159C168563851 @default.
• W4249297159 hasConceptScore W4249297159C203092338 @default.
• W4249297159 hasConceptScore W4249297159C204787440 @default.
• W4249297159 hasConceptScore W4249297159C27081682 @default.
• W4249297159 hasConceptScore W4249297159C2776176026 @default.
• W4249297159 hasConceptScore W4249297159C2779494336 @default.
• W4249297159 hasConceptScore W4249297159C2779637338 @default.
• W4249297159 hasConceptScore W4249297159C2780014101 @default.
• W4249297159 hasConceptScore W4249297159C2780056395 @default.
• W4249297159 hasConceptScore W4249297159C2780580376 @default.
• W4249297159 hasConceptScore W4249297159C2780659260 @default.
• W4249297159 hasConceptScore W4249297159C2780852908 @default.
• W4249297159 hasConceptScore W4249297159C2780959883 @default.
• W4249297159 hasConceptScore W4249297159C2991743468 @default.
• W4249297159 hasConceptScore W4249297159C42219234 @default.

• next